Immuron Limited (IMRN)
NASDAQ: IMRN · Real-Time Price · USD
1.560
-0.050 (-3.11%)
Nov 13, 2025, 4:00 PM EST - Market closed
Immuron Revenue
In the fiscal year ending June 30, 2025, Immuron had annual revenue of 7.29M AUD with 48.63% growth. Immuron had revenue of 3.29M in the half year ending June 30, 2025, with 169.66% growth.
Revenue (ttm)
7.29M AUD
Revenue Growth
+48.63%
P/S Ratio
2.44
Revenue / Employee
1,041,000 AUD
Employees
7
Market Cap
11.65M USD
Revenue Chart
* This company reports financials in AUD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 7.29M | 2.38M | 48.63% |
| Jun 30, 2024 | 4.90M | 3.10M | 171.67% |
| Jun 30, 2023 | 1.80M | 1.04M | 135.85% |
| Jun 30, 2022 | 765.19K | 619.42K | 424.91% |
| Jun 30, 2021 | 145.78K | -2.37M | -94.21% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
IMRN News
- 8 days ago - Immuron IMM-529 IND approved by FDA - GlobeNewsWire
- 27 days ago - Emerging Growth Research Initiates Coverage on Immuron Limited with a Buy-Extended Rating and $4.00 Price Target - Newsfile Corp
- 4 weeks ago - Immuron Q1 FY26 YoY growth - GlobeNewsWire
- 5 weeks ago - Immuron Submits IMM-529 IND to FDA - GlobeNewsWire
- 6 weeks ago - Immuron Letter to Shareholders – Projects Update - GlobeNewsWire
- 2 months ago - Immuron partners with InvestorHub - GlobeNewsWire
- 4 months ago - Immuron - FY25 global sales exceed projection, up 49% on prior year - GlobeNewsWire
- 5 months ago - Immuron Letter to Shareholders: Projects Update - GlobeNewsWire